The Leona M. and Harry B. Helmsley Charitable Trust has awarded the Critical Path Institute (C-Path) a grant to support a Crohn’s disease biomarker preconsortium. The preconsortium will identify unmet needs for the use of biomarkers in developing new treatments for people with Crohn’s disease.
Currently, lack of regulatory endorsement for tools such as biomarkers is hindering the rapid development and approval of improved treatments for Crohn’s disease patients. The preconsortium will focus on identifying Crohn’s disease biomarkers and laying the groundwork for future regulatory endorsement. The long-term objective is to validate and obtain regulatory qualification of biomarkers, which will enable drug developers and the broader Crohn’s disease community of clinicians and researchers to accelerate the development and approval of treatments for those living with the disease.
John-Michael Sauer, PhD, C-Path Biomarker.
“At C-Path, we work collaboratively to identify mechanisms to address areas of unmet need,” says John-Michael Sauer, PhD, program officer at C-Path Biomarker. “The partnership and support from Helmsley will allow us to define the most effective approach to forming a Crohn’s Disease biomarker consortium to take forward the best biomarkers into regulatory qualification.”
“Helmsley is committed to improving the quality of life, advancing better treatments, and ultimately finding cures for Crohn’s disease patients,” says Garabet Yeretssian, PhD, director of the Crohn’s disease program at the Helmsley Charitable Trust. “C-Path’s initiative to identify and position Crohn’s disease-specific biomarkers for regulatory endorsement is a pivotal step in getting improved therapies into the hands of people living with Crohn’s disease more quickly than currently possible.”
For more information, visit C-Path.
